Early Itch Response With Abrocitinib Is Associated With Later Efficacy Outcomes in Patients With Moderate to Severe Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
Am J Clin Dermatol 2022 Dec 13;[EPub Ahead of Print], S Ständer, SG Kwatra, JI Silverberg, EL Simpson, JP Thyssen, G Yosipovitch, F Zhang, MC Cameron, RR Cella, H Valdez, M DiBonaventura, C FeeneyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.